| The Transparent Safety Study of the 5 in 1 (DTwP-rHepB-Hib) Combination Vaccine Produced by the Indian Serine Institute in Children of Viet Nam Healthy From 6 to 12 Weeks of Age in a 3-dose Regimen, the Interval Between Doses is 4 Weeks (NCT03931239) | Vabiotech | 2018-03-01 |
| Evaluation of Immunogenicity and Safety of DTPa-IPV/Hib Conjugate Vaccine (Infanrix™-IPV/Hib) Administered at 6, 10 and 14 Weeks in Healthy Indian Infants (NCT03128489) | GlaxoSmithKline | 2017-12-01 |
| Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery (NCT02853929) | GlaxoSmithKline | 2016-09-19 |
| A Study to Assess the Immunogenicity and Safety of GSK Biologicals' Infanrix-IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in Russia (NCT02858440) | GlaxoSmithKline | 2016-09-13 |
| Immunogenicity and Safety of Sanofi Pasteur's Combined Vaccine Given as a Three-Dose Primary Series at 2, 3,4 Months of Age and Followed by a Booster Dose Given at 16 to 17 Months of Age in Vietnamese Infants Who Previously Received a Dose of Hepatitis B Vaccine at Birth or Within 1 Week After Birth (NCT02428491) | Sanofi Pasteur, a Sanofi Company | 2015-04-20 |
| Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants (NCT02096263) | GlaxoSmithKline | 2014-04-16 |
| Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age (NCT01978093) | GlaxoSmithKline | 2014-02-01 |
| Antibody Persistence at Age 3.5 and 4.5 Years After Primary and Booster DTaP-IPV-Hep B-PRP~T or Infanrix Hexa Vaccination (NCT01983540) | Sanofi Pasteur, a Sanofi Company | 2013-10-01 |
| Randomized Controlled Trial of the Impact of Mobile Phone Delivered Reminders and Travel Subsidies to Improve Childhood Immunization Coverage Rates and Timeliness in Western Kenya (NCT01878435) | Johns Hopkins Bloomberg School of Public Health | 2013-10-01 |
| Safety of GSK Biologicals' Infanrix-IPV+HibTM Vaccine in Healthy Vietnamese Toddlers (NCT01577732) | GlaxoSmithKline | 2012-12-08 |
| Immunogenicity and Safety Study in Infants of GlaxoSmithKline Biologicals' Infanrix Hexa™ (DTPa-HBV-IPV/Hib) Vaccine (NCT01353703) | GlaxoSmithKline | 2012-04-16 |
| Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744) (NCT01453998) | GlaxoSmithKline | 2011-10-14 |
| Immunogenicity and Safety Study of Booster Dose of GSK Biologicals' IPV (Poliorix™) and DTPa/Hib (Infanrix+Hib™) Vaccine (NCT01449812) | GlaxoSmithKline | 2011-10-01 |
| Study to Evaluate Antibody Persistence in Children Previously Vaccinated With Infanrix Hexa™ or Infanrix-IPV/Hib™ (NCT01358825) | GlaxoSmithKline | 2011-05-30 |
| Immunogenicity and Safety of GlaxoSmithKline Biologicals' Infanrix™-IPV+Hib Vaccine (NCT01309646) | GlaxoSmithKline | 2011-03-04 |
| Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744) (NCT01248884) | GlaxoSmithKline | 2010-12-09 |
| Study of PENTAXIM™ Vaccine Versus TETRAXIM™ Vaccine Given With ACTHIB™ Vaccine in South Korean Infants. (NCT01214889) | Sanofi | 2010-09-01 |
| Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster Dose (NCT01171989) | GlaxoSmithKline | 2010-08-18 |
| Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Versus ActHIB & Pentacel in Healthy Infants (NCT01000974) | GlaxoSmithKline | 2010-06-18 |
| Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants (NCT01090453) | GlaxoSmithKline | 2010-05-17 |
| Study to Evaluate the Immunogenicity and Reactogenicity of a Booster Dose of GSK2036874A Vaccine in Healthy Toddlers (NCT01106092) | GlaxoSmithKline | 2010-05-13 |
| Immunogenicity and Safety Study of GSK Biologicals' Infanrix-IPV+Hib™ Vaccine (NCT01086423) | GlaxoSmithKline | 2010-03-01 |
| A Study of DTaP//PRP-T Combined Vaccine (ACTACEL) Versus Local DTaP and Act-HIB Monovalent Vaccine in Healthy Infants (NCT01062477) | Sanofi | 2010-01-01 |
| Safety Study of GSK Biologicals' DTPa-IPV/Hib (Infanrix™-IPV/Hib) (NCT00964028) | GlaxoSmithKline | 2009-12-01 |
| Immunogenicity and Safety Study of GSK Biologicals' GSK2202083A Vaccine in Healthy Infants at 2, 3 and 4 Months of Age (NCT00970307) | GlaxoSmithKline | 2009-08-13 |
| Study to Evaluate GSK Biologicals' GSK2197870A Vaccine Given as Primary Course in Infants (NCT00871338) | GlaxoSmithKline | 2009-06-24 |
| Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hib Vaccines (NCT00891176) | GlaxoSmithKline | 2009-05-14 |
| Feasibility Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 3, 5 and 11 Months of Age. (NCT00871741) | GlaxoSmithKline | 2009-04-01 |
| Safety, Long Term Immunogenicity and Lot Consistency Study of Liquid Pentavalent Combination Vaccine (NCT00877357) | Shantha Biotechnics Limited | 2009-01-01 |
| Safety and Immunogenicity of a Monovalent Conjugated Vaccine Against Haemophilus Influenzae Type b (NCT00808392) | Novartis Vaccines | 2008-11-01 |
| Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants (NCT00753649) | GlaxoSmithKline | 2008-09-23 |
| Safety and Reactogenicity of a Monovalent Conjugated Vaccine Against Haemophilus Influenzae Type b (NCT00734565) | Novartis Vaccines | 2008-07-01 |
| Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Infanrix®Hexa in Healthy Peruvian Infants (NCT00831753) | Sanofi Pasteur, a Sanofi Company | 2008-05-01 |
| Safety and Immunogenicity Study of a Liquid Pentavalent Combination Vaccine (NCT00617812) | Shantha Biotechnics Limited | 2008-03-01 |
| Phase IV Interchangeability Study of a Liquid Pentavalent Combination Vaccine (NCT00674908) | Shantha Biotechnics Limited | 2008-03-01 |
| Immunogenicity and Reactogenicity of a Booster Dose of GSK Bio's DTPa-HBV-IPV/Hib Vaccine (NCT00627458) | GlaxoSmithKline | 2008-02-01 |
| Primary & Booster Study to Evaluate the Immunogenicity and Safety of Menitorix Vaccine in Preterm Infants (NCT00586612) | GlaxoSmithKline | 2007-12-01 |
| Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB-PRP~T Combined Vaccine or Tritanrix-HepB/Hib™ (NCT00534833) | Sanofi Pasteur, a Sanofi Company | 2007-09-01 |
| Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age. (NCT00345683) | GlaxoSmithKline | 2007-07-01 |
| Study of Long-term Antibody Persistence After a Booster Dose of Menitorix Vaccine (NCT00454987) | GlaxoSmithKline | 2007-05-16 |
| Seroimmunity 2007 and Sub Study of the Swedish Population Regarding Vaccine Preventable Disease (NCT00932269) | Swedish Institute for Infectious Disease Control | 2007-03-01 |
| Immunogenicity and Safety of Pentaxim as 3 Doses Primary Vaccination Followed by a Booster Dose at 18 Months (NCT00453570) | Sanofi | 2007-03-01 |
| Study of Modified Process Hib/Hep B Vaccine in Infants (V121-019)(COMPLETED) (NCT00441012) | Merck Sharp & Dohme LLC | 2006-12-01 |
| Immunogenicity and Safety of a DTPa-HBV-IPV/Hib Vaccine Given at 2, 3 and 4 Months of Age (NCT00376779) | GlaxoSmithKline | 2006-10-01 |
| Comparison of a DTaP-IPV-HB-PRP~T Combined Vaccine to Infanrix™-Hexa, When Administered With Prevnar® in Thai Infants (NCT00401531) | Sanofi Pasteur, a Sanofi Company | 2006-10-01 |
| Study to Assess the Safety & Reactogenicity of GSK Biologicals' DTPa/Hib Vaccine When Given at 3, 4 and 5 Months of Age (NCT00379977) | GlaxoSmithKline | 2006-09-01 |
| Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age (NCT00345579) | GlaxoSmithKline | 2006-09-01 |
| Long-Term Antibody Persistence at 1, 3 and 5 Years After a Fourth Dose of GSK Biologicals' Hib-MenCY-TT Vaccine Compared to ActHIB (NCT00359983) | GlaxoSmithKline | 2006-09-01 |
| Comparison of DTaP-IPV-Hep B-PRP~T Combined Vaccine to CombAct-HIB® Concomitantly Given With Engerix B® Paediatric and OPV (NCT00362336) | Sanofi Pasteur, a Sanofi Company | 2006-08-01 |
| Study to Compare Pediacel® to Infanrix®-IPV+Hib When Both Are Co-Administered With Prevenar® in Infants and Toddlers (NCT00343421) | Sanofi Pasteur, a Sanofi Company | 2006-07-01 |
| Safety of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Tritanrix-HepB/Hib™ and OPV Given at Age 2, 4, and 6 Months. (NCT00313911) | Sanofi Pasteur, a Sanofi Company | 2006-07-01 |
| Study in Toddlers to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC & to Evaluate Persistence up to 5 Years. (NCT00326118) | GlaxoSmithKline | 2006-06-01 |
| Long-term Persistence Study to Assess a Booster Dose of GSK Biologicals' Hib-MenC (NCT00322335) | GlaxoSmithKline | 2006-05-01 |
| Primary & Booster Study in Infants to Demonstrate Non-inferiority, Persistence & Immunogenicity of Hib-MenC Vaccine (NCT00327184) | GlaxoSmithKline | 2006-04-01 |
| Immuno & Safety Study With 2 Formulations of DTPw-HBV/HIB When Given at Birth With Hepatitis B at 2, 4 and 6 Mths.Age. (NCT00316680) | GlaxoSmithKline | 2006-03-01 |
| Lot-to-lot Consistency of Tritanrix™-HepB/Hib-MenAC & Its Non-inferiority vs Tritanrix™-HepB/Hiberix™ in Infants (NCT00197275) | GlaxoSmithKline | 2006-02-01 |
| Comparison of Safety and Immunogenicity of Pediacel™ and Infanrix™ IPV+Hib (Penta) Given in a 3 Dose Schedule in Infants (NCT00287092) | Sanofi Pasteur, a Sanofi Company | 2006-02-01 |
| Immunogenicity & Safety of GSK's Combined DTPa-HBV-IPV/Hib Vaccine in Indian Infants at 2 Diff Vaccination Schedules (NCT00316147) | GlaxoSmithKline | 2005-12-01 |
| Multicentre Booster & Immune Memory Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine or a Single Dose of 23-valent Plain Polysaccharide Vaccine in Healthy Children Aged 11-18 Mths, Previously Vaccinated in Study 103488 (NCT00307567) | GlaxoSmithKline | 2005-11-01 |
| Safety Study of Tritanrix-HepB/Hib-MenAC, Tritanrix-HepB/Hiberix, and Mencevax ACWY Vaccines in Children (NCT00228917) | GlaxoSmithKline | 2005-06-16 |
| Hib-MenCY-TT Vaccine Study Compared to Licensed Hib and Meningococcal Serogroup C Conjugate Vaccines (NCT00134719) | GlaxoSmithKline | 2005-04-11 |
| Safety, Reactogenicity & Immunogenicity Study to Evaluate a Booster Dose of GSK Biologicals' Hib-MenC Given With Priorix™ in Toddlers (13-14 m) Primed With 3 Doses of Hib and MenC-CRM197 (NCT00263653) | GlaxoSmithKline | 2005-03-01 |
| Immune Memory of DTPw-HBV/Hib Vaccine Following Primary Vaccination, Immuno & Reacto of a Booster Dose Given in Infants (NCT00169442) | GlaxoSmithKline | 2005-02-10 |
| Primary & Booster Immunogenicity Study of GSK Biologicals' Hib-MenC Versus a Licensed Men-C Vaccine (NCT00258700) | GlaxoSmithKline | 2005-02-01 |
| Assess the Safety & Reactogenicity of DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 & 18 Mths of Age, in Healthy Infants (NCT00325156) | GlaxoSmithKline | 2004-11-02 |
| Study of a Booster Dose of Hib-MenC Conjugate Vaccine vs Infanrix Hexa When Given to 14 Month Old Subjects (NCT00323050) | GlaxoSmithKline | 2004-11-01 |
| Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® PEDIATRICO in Argentinean Infants (NCT00831311) | Sanofi Pasteur, a Sanofi Company | 2004-10-01 |
| Immunogenicity & Safety Study of a Vaccine Against Meningitis in Infants (2,4,6 Months) After a Hepatitis B Birth Dose. (NCT00317161) | GlaxoSmithKline | 2004-08-01 |
| Comparison of GSKBiologicals' Hib-MenCY-TT Vaccine vs Licensed Hib Conjugate or Meningococcal Vaccine (NCT00129129) | GlaxoSmithKline | 2004-08-01 |
| Safety Study of a Vaccine Against Meningitis in Infants (2,4 & 6 Months Age) After a Birth Dose of Hepatitis B. (NCT00317187) | GlaxoSmithKline | 2004-06-08 |
| Assess if Immune Response of GSK Biologicals' Tritanrix™-HepB/Hib-MenAC Given Without or With Hepatitis B Vaccine at Birth is at Least as Good as Tritanrix™-HepB/Hiberix™ Without Hepatitis B Vaccine at Birth, When Given to Healthy Infants (NCT00290303) | GlaxoSmithKline | 2004-05-01 |
| Safety Study of a Vaccine Against Meningitis in Infants ( 2,4 & 6 Months Age) After a Birth Dose of Hepatitis B. (NCT00317135) | GlaxoSmithKline | 2003-12-11 |
| Safety of DTPa-IPV/Hib & DTPa-HBV-IPV/Hib, Followed by DTPa-IPV/Hib Vaccine in Infants Who Received Hepatitis B Vaccine (NCT00325143) | GlaxoSmithKline | 2003-12-01 |
| Comparison of Immunogenicity and Reactogenicity of INFANRIX™ HEXA and HEXAVAC™ Vaccines as a Primary Vaccination Course (NCT01457547) | GlaxoSmithKline | 2003-10-01 |
| Assessment of the Immunogenicity and Safety of PENTAXIM™ in Philippines (NCT00254917) | Sanofi | 2003-10-01 |
| A Study to Assess Antibody Persistence, Boostability & Safety in Previously Primed Subjects. (NCT00317174) | GlaxoSmithKline | 2003-07-01 |
| The Immediate and Longterm Immune Responses of UK Infants and Young Children to a Booster Dose of Hib Vaccine (NCT00197782) | Public Health England | 2003-04-01 |
| Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) Vaccine (NCT00127855) | GlaxoSmithKline | 2003-03-01 |
| 3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of Age (NCT00129116) | GlaxoSmithKline | 2003-03-01 |
| Study of the Safety, Immunogenicity and Lot Comparability of DAPTACEL When Administered With Other Recommended Vaccine (NCT00662870) | Sanofi | 2001-05-01 |
| Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib Vaccine Followed by the Same Vaccine and Oral Polio Vaccine (NCT01457560) | GlaxoSmithKline | 2000-02-01 |